Pipeline news

• Clearside Biomedical Establishes Scientific Advisory Board with Distinguished Retinal Physicians

  09 April 2020

  

  Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today the formation of a  Scientific Advisory Board  comprised of world-renowned retinal physicians to advise on the Company’s research and development programs. 

• Marinus Pharmaceuticals Provides Business Reports Update and 2019 Financial Results

  18 March 2020

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided a business update on its clinical development activities and reported its financial results for the year ended December 31, 2019.

• Clearside Biomedical Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

  11 March 2020

  

  Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the fourth quarter and year ended  December 31, 2019  and provided a corporate update.

• Clearside Biomedical Announces License Agreement with Arctic Vision for XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) in Greater China and South Korea

  11 March 2020

  

  Clearside Biomedical , Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Arctic Vision, a company focused on developing and commercializing innovative ophthalmology therapies in  China  and  Asia , has acquired an exclusive license for the commercialization and development of XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) in Greater China (mainland  China ,  Hong Kong ,  Macau  and  Taiwan ) and  South Korea .

• Clearside Biomedical Appoints Dr. George Lasezkay as President and Chief Executive Officer

  11 March 2020

  

  Clearside Biomedical , Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., has been appointed President and Chief Executive Officer. He will continue to serve on the Board of Directors. This appointment was effective  March 1, 2020.

• Syndax Pharmaceuticals Reports Fourth Quarter 2019 Financial Results and Provides Clinical and Business Update

  03 March 2020

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended  December 31, 2019 . In addition, the Company provided a clinical and business update. As of  December 31, 2019 , Syndax had  $59.8 million  in cash, cash equivalents and short-term investments.

• Marinus Pharmaceuticals Completes Targeted Enrollment in Pivotal Phase 3 Study for CDKL5 Deficiency Disorder

  25 February 2020

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced it has reached the 100 patient enrollment target for the Marigold Study.  The Marigold Study is a pivotal Phase 3 study evaluating oral ganaxolone in children and young adults with CDKL5 Deficiency Disorder (CDD), a rare refractory form of pediatric epilepsy with no currently approved treatments.  The Company will continue enrollment through the end of the month to capture the remaining few patients in the screening phase.  Marinus is on-track to report top-line results in the third quarter of 2020.

• Syndax Announces $35.0 Million Offering of Common Stock and Enters Term Sheet for Loan with Hercules Capital for up to $30 Million

  31 January 2020

  

  Syndax Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with five leading life sciences investors, including  Biotechnology Value Fund, L.P. ,  Boxer Capital  and  AI Life Sciences Investments LLC , an affiliate of  Access Industries Inc. , for the purchase of common stock at  $8.00  per share, representing a premium of 20% to the share price as of market close on  Thursday, January 30, 2020 . Syndax anticipates aggregate gross proceeds from the offering will be approximately $35.0 million. 

• Science Magazine Publishes Results from Preclinical Study on the Activity of Menin-MLL Inhibition for the Treatment of NPM1 Acute Myeloid Leukemia

  30 January 2020

  

  Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Science magazine has published a preclinical report supporting the potential role of MLL1-Menin inhibition in the management of nucleophosmin (NPM1) mutant acute myeloid leukemia (AML). 

• Bausch Health and Clearside Biomedical Announce Publication of PIVOTAL Phase 3 Data ON XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) in Ophthalmology

  28 January 2020

  

  Bausch Health Companies Inc.  (NYSE/TSX: BHC) (" Bausch Health ") and Bausch + Lomb, its leading global eye health business, and  Clearside Biomedical , Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Ophthalmology, the peer-reviewed journal of the  American Academy of Ophthalmology , has published results from the randomized, controlled, double-masked Phase 3 clinical trial (PEACHTREE study) of XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension), an investigational therapy with a proposed indication of treatment of macular edema associated with uveitis.¹